Overview

• The JM2 peptide selectively disrupts connexin43-microtubule interactions in glioblastoma stem cells, triggering their death while sparing normal brain cells.
• In vivo experiments show that JM2 treatment significantly reduces tumor growth in mouse models of glioblastoma.
• Researchers uncovered a novel role for cytoplasmic connexin43 in maintaining treatment-resistant stem cells, guiding the design of JM2.
• Teams are exploring biodegradable nanoparticle and viral vector platforms to deliver JM2 directly to tumor sites.
• Co-founders Samy Lamouille and Rob Gourdie formed Acomhal Research Inc. to license JM2 and advance it toward clinical trials.